A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181504
- Locations
- 🇯🇵
Nihon University Hospital, Chiyoda-ku,Tokyo, Japan
🇯🇵1 Fukushima Medical University, Fukushima-shi, Japan
🇯🇵Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
Completed
- Conditions
- Macular EdemaRetinal Vein Occlusion
- Interventions
- Other: No Intervention
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 43
- Registration Number
- NCT02181530
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181517
A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area
Not Applicable
Completed
- Conditions
- Infra-orbital Skin Depressions
- Interventions
- Device: VOLBELLA® with lidocaine
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 80
- Registration Number
- NCT02176421
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
Phase 4
Completed
- Conditions
- Glabellar LinesFacial RhytidesCrow's Feet LinesNasolabial Fold
- Interventions
- Biological: onabotulinumtoxinADevice: JUVÉDERM® ULTRA XCDevice: JUVÉDERM® ULTRA PLUS XCDevice: JUVÉDERM® VOLUMA® XC
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 116
- Registration Number
- NCT02176356
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
Completed
- Conditions
- Urinary IncontinenceUrinary Bladder, Overactive
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 515
- Registration Number
- NCT02161159
- Locations
- 🇩🇪
Andreas Reinhard Wicht, Sangerhausen, Germany
🇩🇪Franz Hirschle, Singen, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Conjunctivitis, Allergic
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 240
- Registration Number
- NCT02161146
A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AGN-223575 VehicleDrug: AGN-223575 Formulation ADrug: AGN-223575 Formulation BDrug: AGN-223575 Formulation C
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Allergan
- Target Recruit Count
- 51
- Registration Number
- NCT02155543
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Phase 3
Completed
- Conditions
- LeiomyomaUterine Hemorrhage
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 157
- Registration Number
- NCT02147197
- Locations
- 🇺🇸
Watson Investigational Site 103, Atlanta, Georgia, United States
🇺🇸Watson Investigational Site 115, Lakewood, Colorado, United States
🇺🇸Watson Investigational Site 111, Augusta, Georgia, United States
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
Phase 3
Completed
- Conditions
- Uterine HemorrhageLeiomyoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 432
- Registration Number
- NCT02147158
- Locations
- 🇺🇸
Watson Investigational Site 108, Las Vegas, Nevada, United States
🇺🇸Watson Investigational Site 107, Las Vegas, Nevada, United States
🇺🇸Watson investigational site 142, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath